Innovative therapeutics

Investors

Financial Statements

NASDAQBMRN
All numbers in thousands USD
Period Ending
Sep 30, 2016
Jun 30, 2016
Mar 31, 2016
Dec 31, 2015
Total Revenue
279,896
300,131
236,736
227,936
Cost of Revenue
50,738
51,617
43,118
48,043
Gross Profit
229,158
248,514
193,618
179,893
Operating Expenses
Research Development
160,831
167,039
158,793
176,118
Selling General and Administrative
118,758
109,577
105,300
113,907
Non Recurring
--
--
--
--
Others
9,654
544,704
10,442
(211,451)
Total Operating Expenses
289,243
821,320
274,535
78,574
Operating Income or Loss
(60,085)
(572,806)
(80,917)
101,319
Income from Continuing Operations
Total Other Income/Expenses Net
1,619
(1,552)
63
(28,966)
Earnings Before Interest And Taxes
(56,833)
(573,001)
(79,283)
73,804
Interest Expense
9,980
9,944
9,843
(19,161)
Income Before Tax
(66,813)
(582,945)
(89,126)
92,965
Income Tax Expense
(24,016)
(159,385)
(3,984)
24,348
Minority Interest
--
--
--
--
Net Income From Continuing Ops
(42,797)
(423,560)
(85,142)
68,617
Non-recurring Events
Discontinued Operations
--
--
--
--
Extraordinary Items
--
--
--
--
Effect Of Accounting Changes
--
--
--
--
Other Items
0
0
0
0
Net Income
(42,797)
(423,560)
(85,142)
68,617
Preferred Stock And Other Adjustments
--
--
--
--
Net Income Applicable To Common Shares
(42,797)
(423,560)
(85,142)
68,617

BioMarin

Diseases

Lysosomal Storage Disorders (MPS I, MPS IVA, MPS VI) PKU, LEMS

Products

Vimizim®
Kuvan®
Naglazyme®
Aldurazyme®
Firdapse®

Patient/Physician Support Contact Information

BioMarin RareConnections
Tel: 866.906.6100
Fax: 888.863.3361
E-mail: support@biomarin-rareconnections.com

Global Medical Information

Contact Global Medical Information